Erector Spinae Plane Block vs Erector Spinae Plane Block With Serratus Anterior Plane Block in Thoracic Surgery
Launched by ANNA USKOVA · Apr 15, 2020
Trial Information
Current as of May 19, 2025
Withdrawn
Keywords
ClinConnect Summary
Once consented, the patient will be randomized by computer generated random number to one of the two treatment groups.
Blinding Plan: At the acute pain management office, one member of the research team will be responsible for providing the anesthesiologist in charge of performing the block with a sealed envelope. Each envelope will be labeled with a number corresponding to a matching number labeled on each patient binder. This envelope will contain the randomized block to be administered - ESP with SAP or ESP with SAP normal saline. Once the anesthesiologist knows which block combination ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18-80 years old
- • Primary Unilateral Thoracic Surgery
- • BMI 20 - 36, weight \> or = to 50kg
- • Male and Female
- • All races
- Exclusion Criteria:
- • Patient refusal
- • Inpatient status at time of surgery
- • ASA class \> or = 4
- • Bilateral thoracic surgery
- • Pregnancy
- • Non-English speaking or inability to participate in the study
- • Patients with coagulopathy or on therapeutic anticoagulation
- • Chronic Steroid Use
- • Narcotic Addiction
- • Patients with contraindication to performing either block - active infection at block site, systemic infection, allergy to local anesthetic medications
- • Patients undergoing second surgery or urgent/emergent surgery
- • Patients weighing \<50kg
About Anna Uskova
Anna Uskova is a dedicated clinical trial sponsor focused on advancing medical research through innovative and rigorous study designs. With a commitment to enhancing patient outcomes, the organization collaborates closely with healthcare professionals, regulatory bodies, and research institutions to develop and implement clinical trials that adhere to the highest ethical and scientific standards. Driven by a passion for improving health solutions, Anna Uskova aims to accelerate the development of new therapies and contribute to the advancement of medical knowledge across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Dmitriy Gromov, DO
Principal Investigator
University of Pittsburgh Medical Center
Anna Uskova, MD
Study Director
University of Pittsburgh Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials